BLUE bluebird bio, Inc.

83.00
-1  -1%
Previous Close 83.95
Open 84.35
Price To book 3.93
Market Cap 3.39B
Shares 40,844,000
Volume 988,763
Short Ratio 8.80
Av. Daily Volume 725,890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017. Abstract 3010
bb2121
Relapsed/refractory multiple myeloma
Noted on December 14, 2016 that Phase 3 dosing has commenced. Early data due at EHA 2017. Exact date TBC.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 trial initiated October 2013. Interim data released at AAN Conference April 20, 2016.
Lenti-D
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data presented at ASH December 5, 2016.
LentiGlobin - HGB-204
β-Thalassemia
Update at ASH 2016. Further data due at ASH 2017. Exact date TBC.
LentiGlobin - HGB-206
Sickle disease

Latest News

  1. bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : April 17, 2017
  2. bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : April 13, 2017
  3. bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives
  4. 3 tech and biotech stocks with momentum
  5. Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.
  6. Four biotech stocks surging on optimism about drug trials, product launches
  7. bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine
  8. Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals
  9. Kite Pharma's cancer drug clears main goal in study
  10. bluebird bio to Present at Two Investor Conferences in March
  11. bluebird bio, Inc. :BLUE-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017
  12. bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q4, 2016 By the Numbers : February 24, 2017
  13. bluebird bio Inc Highlights a Data-Rich 2017
  14. Bluebird Bio 4Q Loss Below Street Estimates
  15. Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year'
  16. Bluebird reports 4Q loss
  17. bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress
  18. Three Biotechs With Bullish Basing Patterns
  19. Why bluebird bio Stock Surged 20.7% Higher in January
  20. 3 Scorching Hot Biotech Stocks -- Are They Buys?